PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly

The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to:

• characterize participants in terms of geriatrics, biology and carcinology
• describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life.

At the same time, exploratory sub-cohorts will be identified including participants treated uniformly with the same molecule, and/or the same innovative strategy.

Participants will be followed in accordance with investigator's usual clinical practice at the corresponding site. They will be asked to:

• visit the clinic as per physician's request for checkups and tests for assessing general condition and clinical efficacy and tolerance of current treatment.
• perform the necessary regular para-clinical examinations (lab testing, imaging, re-biopsy).
• provide blood samples for bio-bank repository
• perform assessments specific to older adults
• answer three quality of life questionnaires

Inclusion Criteria:

• Patient ≥70 years
• Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage
• Patient naïve to systemic anticancer treatment for bronchial neoplasia
• Patient covered by social security
• Patient eligible for systemic treatment
• Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.
• Patient able to understand the protocol
• Patient not opposed to the collection of data concerning him/her
• Signature of study consent form.

Exclusion Criteria:

• Patients under guardians or curators
• Patient not under the care of the investigating center and not monitored by the investigating center
• Patient already treated with systemic therapy for NSCLC